Get started

Financials · ADXN

Addex Therapeutics Ltd (ADXN) financials

For fiscal 2025 (ended Dec 31, 2025), Addex Therapeutics Ltd reported CHF 172.9K of revenue and -CHF 6.73M of net income. Figures are in CHF, the currency of its SEC filings.

Revenue, FY2025
CHF 172.9K
Revenue growth, YoY
-57.8%
Net income, FY2025
-CHF 6.73M
Net margin
-3892.3%
Free cash flow, FY2025
-CHF 2.17M
EPS, diluted, FY2025
-CHF 0.06
Cash
CHF 1.64M
Total debt
CHF 0
Annual revenueCHF 172.9K
FY2017FY2025
Annual net income-CHF 6.73M
FY2017FY2025
Annual free cash flow-CHF 2.17M
FY2017FY2025

ADXN revenue and earnings growth

ADXN revenueFY2025CHF 172.9K

FY YoY
-57.8%
5Y CAGR
-46.3%

ADXN revenue was CHF 172.9K for fiscal 2025 (ended Dec 31, 2025), down 57.8% from fiscal 2024. Compound annual growth was -46.3% over 5 years. It rose in 3 of the last 8 fiscal years.

ADXN net incomeFY2025-CHF 6.73M

ADXN net income was -CHF 6.73M for fiscal 2025 (ended Dec 31, 2025), compared with CHF 7.06M in fiscal 2024.

ADXN EPSFY2025-CHF 0.06

ADXN diluted EPS was -CHF 0.06 for fiscal 2025 (ended Dec 31, 2025), compared with CHF 0.07 in fiscal 2024.

ADXN free cash flowFY2025-CHF 2.17M

ADXN free cash flow was -CHF 2.17M for fiscal 2025 (ended Dec 31, 2025), compared with -CHF 5.37M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
RevenueCHF 172.9KCHF 410.0KCHF 1.62MCHF 1.44MCHF 3.15MCHF 3.88MCHF 2.83MCHF 6.70MCHF 499.9K
Research and developmentCHF 671.7KCHF 854.3KCHF 1.19MCHF 8.24MCHF 12.84MCHF 10.37MCHF 12.45MCHF 4.92MCHF 2.63M
Selling, general and adminCHF 2.32MCHF 2.31MCHF 2.67MCHF 3.74MCHF 5.82MCHF 5.75MCHF 4.98MCHF 3.21MCHF 1.11M
Operating income-CHF 2.81M-CHF 2.76M-CHF 2.24M-CHF 10.54M-CHF 15.51M-CHF 12.24M-CHF 14.60M-CHF 1.42M-CHF 3.24M
Interest expenseCHF 487CHF 1.6KCHF 1.6KCHF 2.1KCHF 39.1KCHF 50.5KCHF 105.9KCHF 134.3KCHF 171
Pre-tax income-CHF 6.84M-CHF 4.91M-CHF 2.50M-CHF 10.80M-CHF 15.35M-CHF 12.86M-CHF 14.78M-CHF 1.64M-CHF 3.28M
Income taxCHF 0CHF 0CHF 0CHF 0CHF 0CHF 0CHF 0CHF 0-
Net income-CHF 6.73MCHF 7.06M-CHF 10.56M-CHF 20.80M-CHF 15.35M-CHF 12.86M-CHF 14.78M-CHF 1.64M-CHF 3.28M
EPS, basic-CHF 0.06CHF 0.07-CHF 0.14-CHF 0.46-CHF 0.45-CHF 0.48-CHF 0.56--
EPS, diluted-CHF 0.06CHF 0.07-CHF 0.14-CHF 0.46-CHF 0.45-CHF 0.48-CHF 0.56--
Diluted shares107.4M98.1M74.3M45.2M34.1M26.7M26.4M23.3M12.9M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Cash and equivalentsCHF 1.64MCHF 3.34MCHF 3.87MCHF 6.96MCHF 20.48MCHF 18.70MCHF 31.54MCHF 31.54MCHF 2.58M
ReceivablesCHF 20.1KCHF 15.5KCHF 110.4KCHF 416.9KCHF 164.8KCHF 68.4KCHF 118.0KCHF 273.0K-
Current assetsCHF 1.68MCHF 3.54MCHF 4.23MCHF 7.83MCHF 21.94MCHF 19.49MCHF 32.39MCHF 42.15M-
Total assetsCHF 6.36MCHF 10.68MCHF 4.64MCHF 8.28MCHF 22.54MCHF 20.18MCHF 33.03MCHF 42.21M-
Current liabilitiesCHF 1.20MCHF 802.1KCHF 2.89MCHF 3.28MCHF 4.13MCHF 3.62MCHF 5.68MCHF 2.33M-
Short-term debtCHF 0CHF 0CHF 0CHF 0CHF 0CHF 0CHF 0CHF 0-
Long-term debtCHF 0CHF 0CHF 0CHF 0CHF 0CHF 0CHF 0CHF 0-
Total debtCHF 0CHF 0CHF 0CHF 0CHF 0CHF 0CHF 0CHF 0-
Total liabilitiesCHF 1.60MCHF 1.00MCHF 3.50MCHF 3.37MCHF 5.61MCHF 5.57MCHF 7.50MCHF 2.97M-
Shareholders' equityCHF 4.77MCHF 9.68MCHF 1.15MCHF 4.91MCHF 16.93MCHF 14.61MCHF 25.52MCHF 39.24MCHF 1.34M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Operating cash flow-CHF 2.17M-CHF 5.37M-CHF 7.99M-CHF 16.44M-CHF 14.71M-CHF 12.18M-CHF 9.48MCHF 1.75M-CHF 2.14M
Capital expendituresCHF 0CHF 1.3KCHF 6.8KCHF 581CHF 31.5KCHF 59.4KCHF 28.5KCHF 9.1KCHF 697
Free cash flow-CHF 2.17M-CHF 5.37M-CHF 8.00M-CHF 16.44M-CHF 14.74M-CHF 12.24M-CHF 9.51MCHF 1.74M-CHF 2.14M
Investing cash flow-CHF 680.7KCHF 4.65M-CHF 6.8KCHF 3.0K-CHF 30.3K-CHF 59.4K-CHF 43.3K-CHF 56.4K-CHF 697
Financing cash flowCHF 1.18MCHF 104.9KCHF 5.26MCHF 3.10MCHF 16.40MCHF 46.4K-CHF 463.7KCHF 37.39MCHF 3.36M
Stock-based compensationCHF 70.8KCHF 503.0KCHF 1.79MCHF 3.68MCHF 1.18MCHF 1.18MCHF 1.69MCHF 2.30MCHF 800.2K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue growth, YoY-57.8%-74.6%11.9%-54.2%-18.7%36.9%-57.7%1240.8%-
Operating margin-1628.3%-671.9%-138.7%-729.5%-491.7%-315.6%-515.4%-21.3%-647.1%
Net margin-3892.3%1720.7%-652.8%-1439.8%-486.9%-331.5%-521.6%-24.5%-656.2%
Free cash flow margin-1256.0%-1310.8%-494.6%-1137.6%-467.3%-315.5%-335.6%26.0%-428.2%
Return on equity-141.2%72.9%-921.6%-423.5%-90.7%-88.0%-57.9%-4.2%-244.3%
Return on assets-105.7%66.1%-227.4%-251.2%-68.1%-63.7%-44.8%-3.9%-
Current ratio1.404.421.462.395.315.385.7018.06-
Debt to equity0.000.000.000.000.000.000.000.00-

Source: XBRL data Addex Therapeutics Ltd files with the SEC, latest filing dated May 15, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.

ADXN peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ADXNCHF 172.9K-57.8%-CHF 6.73M-3892.3%$4.8M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

ADXN FAQ

8 questions
  • What is ADXN revenue?
    Addex Therapeutics Ltd (ADXN) reported CHF 172.9K of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 57.8% from the year before.
  • Is ADXN profitable?
    No. Addex Therapeutics Ltd reported a net loss of CHF 6.73M for fiscal 2025 (ended Dec 31, 2025).
  • How much cash and debt does ADXN have?
    Addex Therapeutics Ltd reported CHF 1.64M in cash and cash equivalents and CHF 0 of debt on its most recent balance sheet in SEC filings.
  • How fast is ADXN revenue growing?
    Addex Therapeutics Ltd's revenue changed -57.8% in fiscal 2025, to CHF 172.9K. Its compound annual growth rate was -46.3% over 5 years.
  • What is ADXN free cash flow?
    Addex Therapeutics Ltd generated -CHF 2.17M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -CHF 2.17M less capital expenditures.
  • What is ADXN earnings per share?
    Diluted earnings per share were -CHF 0.06 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.
  • When did ADXN last report financial results?
    The latest statements here come from Addex Therapeutics Ltd's 20-F filed on May 15, 2026, covering the period ended Dec 31, 2025.
  • Where does this ADXN financial data come from?
    Quantisnow builds these statements from the structured XBRL data Addex Therapeutics Ltd files with the SEC. It is provided for information only and is not investment advice.